首页> 外文期刊>Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation >Angiogenic Factors, Inflammation, and Outcomes in Myeloablative Allogeneic Hematopoietic Cell Transplantation: A Biomarker Analysis of Gvhd Prophylaxis in Blood and Marrow Transplant Clinical Trials Network Protocol (BMT CTN) 0402

【24h】

Angiogenic Factors, Inflammation, and Outcomes in Myeloablative Allogeneic Hematopoietic Cell Transplantation: A Biomarker Analysis of Gvhd Prophylaxis in Blood and Marrow Transplant Clinical Trials Network Protocol (BMT CTN) 0402

机译：异基因异基因造血细胞移植的血管生成因子，炎症和结果：血液和骨髓移植临床试验网络协议（BMT CTN）0402中预防Gvhd的生物标志物分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation》 |2016年第1期|共2页
作者
Newell Laura F.; Verneris Michael R.; Panoskaltsis-Mortari Angela; Defor Todd E.; Blazar Bruce R.; Cutler Corey S.; Antin Joseph H.; MacMillan Margaret L.; Weisdorf Daniell; Holtan Shernan;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词

相似文献

外文文献
中文文献
专利

1. Angiogenic Factors, Inflammation, and Outcomes in Myeloablative Allogeneic Hematopoietic Cell Transplantation: A Biomarker Analysis of Gvhd Prophylaxis in Blood and Marrow Transplant Clinical Trials Network Protocol (BMT CTN) 0402 [J] . Newell Laura F., Verneris Michael R., Panoskaltsis-Mortari Angela, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2016,第3Suppla1期

机译：异基因异基因造血细胞移植的血管生成因子，炎症和结果：血液和骨髓移植临床试验网络协议（BMT CTN）0402中预防Gvhd的生物标志物分析
2. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402) [J] . Gooptu Mahasweta, Kim Haesook T., Howard Alan, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2019,第11期

机译：None
3. Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703) [J] . Smith Eileen P., Li Hongli, Friedberg Jonathan W., Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2018,第4期

机译：串联自体造血细胞移植患者初级进步或复发性霍奇金淋巴瘤：血液和骨髓移植临床试验网络II次试验（SWOG S0410 / BMT CTN 0703）
4. A clinical trial of prophylactic antifungal therapy in patients undergoing hematopoietic stem cell transplantation [C] . Zhou Qi, Lou Fangding, Zhang Bolong Proceedings of the Fourth China-Jpan international congress of mycology . 1998

机译：造血干细胞移植患者预防性抗真菌治疗的临床试验
5. Pre-Transplant Risk Factors Associated With Worse Outcomes in Adolescents and Young Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation [D] . Friend, Brian. 2018

机译：与经历同种异体造血干细胞移植的青少年和青少年较差的预移植危险因素
6. Tandem Autologous versus Single Autologous Transplantation Followed by Allogeneic Hematopoietic Cell Transplantation for Patients with Multiple Myeloma: Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial [O] . Amrita Krishnan, Marcelo C. Pasquini, Brent Logan, -1

机译：自体串联单与自体移植其次是异基因造血干细胞移植与多发性骨髓瘤患者：从血液和骨髓移植临床试验网络（BmT CTN）0102试验结果
7. Phase II Trial of Non-Myeloablative Conditioning and Partially HLA-Mismatched (HLA-Haploidentical) Bone Marrow Transplantation (BMT) for Patients With Hematologic Malignancies: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0603 [O] . The Johns Hopkins University, Baltimore, MD ( host institution ), Fuchs, E.J., Wu, J., 2011

机译：血液恶性肿瘤患者非清髓性调节和部分HLA不匹配（HLA单倍型）骨髓移植（BMT）的II期试验：血液和骨髓移植临床试验网络（BMT CTN）协议0603的结果

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号